Wednesday September 11, 2024 | 3:00 – 4:00 PM CET
Digital Therapeutics (DTx) are software-based interventions designed to manage or treat medical conditions, offering significant potential to enhance healthcare outcomes. The market, valued at $6.1 billion in 2023, is projected to reach $21.9 billion by 2028, driven by technological advancements and governmental support, though challenged by patient reluctance, prescription complexities, and payment model instability.
Demystifying digital therapeutics reveals a different story. Numerous zero-to-hero success stories showcase how digital health solutions have transformed patient outcomes, streamlined care processes and empowered individuals to manage their health more effectively. These narratives highlight the potential of digital health to overcome initial hurdles and deliver significant, lasting benefits.
In our Climedo Connect on September 11, 2024, Dr. Spencer Jones (Digital Health Consultant and former Executive Director Global Digital Health at Bristol Myers Squibb) shared first-hand insights into the impact and pitfalls of digital health. We also explored the dynamic and rapidly growing field of Digital Therapeutics (DTx).
We discussed:
- Understanding Digital Therapeutics: Definition, market growth and key drivers.
- Real-World Examples: Success stories of improved outcomes, enhanced patient adherence and cost-effectiveness.
- Challenges: Addressing patient reluctance, integration with EHRs, reimbursement models and data security.
- Future Outlook: Personalized solutions, data-driven approaches and collaborative efforts in advancing DTx.
In addition to Spencer's presentation, attendees had the opportunity to gain valuable insights and contribute to the discussion on enhancing patient health and reach.
Meet Our Speakers
Catherine Higginson (Webinar Host)
Associate Director, Marketing & Communications | Climedo
As Climedo's Marketing & Communications Manager and a EUPATI patient fellow, Catherine oversees the areas of industry research, content creation and collaboration with thought leaders and partners for marketing-related projects and events. She is passionate about showcasing the power of hybrid trials and RWE in the pharma and medtech industries.
.png?width=250&name=Spencer-modified%20(3).png "Spencer-modified (3)")
Dr. Spencer Jones
Digital Health Consultant
Spencer is a seasoned professional with over two decades of experience in digital health and medical affairs, including leadership positions at pharma companies like BMS, Novartis and Sandoz. He has witnessed the transformative power of innovative technologies to improve patient care and empower healthcare professionals.
What was on the Agenda?
-
Intro (Catherine Higginson)
-
Digital Therapeutics Unmasked: What Does the Future Hold? (Dr. Spencer Jones)
-
Discussion and networking (all)
- Wrap-up (Catherine Higginson)
Your Takeaways
INSIGHTS
Valuable insights into the opportunities and impact of digital health on patient's quality of life.
BEST PRACTICES
Discover the key levers and pitfals of introducing digital health solutions.
NETWORKING & DISCUSSION
Talking to other industry professionals and finding out how they are tackling challenges similar to yours.
CLIMEDO
The leading European eCOA system for non-interventional studies, RWE and launch success
Climedo offers an all-in-one eCOA and EDC solution with hybrid capabilities for non-interventional studies and real-world evidence. By using a patient-centric approach and leveraging real-time data insights and visualizations around a study’s current progress, Climedo empowers its clients to better engage with healthcare professionals and other key opinion leaders (KOLs). This boosts awareness, stimulates scientific dialogue and accelerates the launch success of new medical innovations, thus reaching more patients faster.
Founded in Munich in 2017, Climedo is a leading trusted partner for pharma, MedTech, CROs and academia with over 1.7 million patients enrolled to date. Learn more at www.climedo.com.
